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Objectives: To review the progression decisions for notifications considered at National
Institute of Health and Care Excellence (NICE) Medical Technology Advisory Committee (MTAC)
meetings during its first three years (2010–2013) to identify trends.
Methods: The list of medical devices discussed at committee, briefing notes, committee
decisions, and non-progression letters, where applicable, were obtained from NICE. Each
medical device presented to committee was classified using five different medical device
categorisation systems. Trends in progression decision, scores against programme selection
criteria over time, and reasons provided by committee to support the non-progression decision,
were analysed.
Results: Between January 2010 and March 2013 31 MTAC meetings were held. Of the 110
medical technologies considered, 45 were given a progression decision (23 selected for Medical
Technologies Guidance development, 22 routed for guidance development in other NICE
programmes), 64 did not progress to guidance development and 1 was excluded from analysis
whilst awaiting final committee decision. The six programme categories and total scores were
not sensitive or specific predictors of progression to guidance decision. No significant change in
the proportion selected for progression over time was observed (P40.05). No compelling
evidence of an association between the type of medical device and progression decision was
found. Fifteen distinct reasons for non-progression were identified; ‘lack of evidence’ being
provided in the majority, 93.8%, of cases..03.003
raduate Medicine. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
licenses/by-nc-nd/4.0/).
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K. Keltie et al.244Conclusions: During its first three years, MTAC's progression decisions for guidance develop-
ment on medical technologies were not associated with device type and there is no evidence of
changes over time.
& 2016 Fellowship of Postgraduate Medicine. Published by Elsevier Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The Medical Technologies Evaluation Programme (MTEP) was
established by NICE in 2009 [1] to identify and encourage
the adoption of novel medical technologies through the
development of national guidance [2,3]. According to the
MTEP processes and methods guides [4,5], manufacturers or
suppliers (sponsors) of technologies initiate the process by
submitting a notification form to NICE. For each notified
medical device, the NICE MTEP team prepares a briefing
note [4] consisting of information drawn from the sponsor's
notification form, background information and expert
advice, then assigns a score based on the extent to which
the technology meets the programme selection criteria [5].
The briefing note is considered by the Medical Technologies
Advisory Committee (MTAC) where it is discussed with
expert advisors during a closed meeting, from which
members of the public and sponsors are excluded. The
committee first decides whether the technology should
progress to full guidance or not. For technologies recom-
mended to progress, MTAC then recommend whether to
select the device for Medical Technologies Guidance (MTG)
development on the basis of its claims and supporting
evidence, or whether to route it to another NICE pro-
gramme for guidance development. A review of the Medical
Technologies Evaluation Programme has recently been pub-
lished by Green and Hutton [6].
Sponsors of topics which MTAC have decided not to
progress to guidance development in any NICE programme
receive a commercial-in-confidence letter from the Com-
mittee chair summarising the committee's considerations
with reference to the selection criteria. The letter may
suggest refinement of the case for adoption or request
development of further evidence (e.g. for a particular
clinical indication), and offers sponsors the opportunity to
contact NICE for more information on the decision. Unless
the sponsor contacts NICE, which might include seeking
advice on re-notification, NICE does not routinely follow up
topics given a non-progression decision.
NICE publishes details of all technologies considered by
MTAC [7], including those not progressed further for guidance
development, although some authors [3] have noted that the
reasons for non-progression are not put into the public
domain. Although this is to avoid potentially discouraging
companies from submitting to the programme, it could be
interpreted as a lack of transparency. This provides the
motivations for the aims of this study, which are to identify
the factors which most strongly influence MTAC in deciding
whether or not to progress a particular technology for full
guidance development, and to establish whether MTAC's
decisions are associated with the characteristics of technolo-
gies. The objectives of this study are to review the progressiondecisions for notifications considered at MTAC meetings during
its first three years (2010–2013); to identify any trends in
progression rate and scores against programme selection
criteria over time (a possible learning curve effect); to classify
the types of medical technology presented to committee; to
test for association between the characteristics of technology
and progression decision, and to summarise the reasons
provided by committee to support their non-progression
decisions.Methods
Publicly available minutes from committee meetings were
obtained for the period January 2010 to March 2013 from
the NICE website [7]. A spreadsheet was compiled of all
medical technologies submitted during this time. Corre-
sponding briefing notes and non-progression letters, if
applicable, were provided by NICE to the authors in
confidence.
The total numbers of medical technologies considered,
the number progressing to full guidance development
(either for MTG development or routed to other NICE
programmes) and those not progressing to guidance at each
committee meeting between January 2010 and March 2013
(inclusive) were assessed from the minutes. Trends (i.e.
presence of a learning curve effect) were assessed by
converting committee meeting dates (when the final pro-
gression decision was made) to integer days counted from
the first committee meeting. The correlation between time
(in days) and the proportion selected for progression was
analysed using Pearson's product-moment correlation [8].
Scripts for data manipulation and statistical analysis were
written in the statistical programming language R (version
3.2.3, R Foundation for Statistical Computing) [9].
Scores assigned by the MTEP team were extracted from
briefing notes. Each criterion is scored on a scale from 1 to
5, where 1 is the worst score and 5 is the best [5]. For
example, a score of 1 for claimed additional benefit to
patients implies the technology is of negligible additional
benefit compared with existing standard care; a score of
5 implies the technology is of significant additional diag-
nostic or therapeutic benefit compared with existing stan-
dard care. For the cost criterion, a score of 1 indicates that
the costs are low and a score of 5 indicates that the costs
are high. In order to match the sense of the other criteria,
the cost score was inverted for analysis and a total score
was calculated for each device.
The distribution of scores was initially tested using the
Shapiro–Wilk test for normality [10], with significant devia-
tion from normal distribution identified when Po0.1 [11].
Total scores and scores for each of the five criteria for all
Figure 1 Cumulative frequency of Medical Technology Advi-
sory Committee decisions: progression to Medical Technologies
Guidance (MTG) development (solid line), progression to gui-
dance in other NICE programmes (dotted line) and those not for
progression to guidance in any NICE programme (dashed line).
245Reviewing NICE MTEP progression decisionstechnologies considered were compared univariately
(against the null hypothesis of no difference between those
selected for progression and those not) using non-
parametric Mann–Whitney U-tests [12]. In addition, the
effect sizes of the five individual criteria scores on the
decision to progress were estimated using multivariate
binary logistic regression analysis with a generalised linear
model [13]. Coefficients of the independent predictor
variables were expressed as odds ratios (with corresponding
95% confidence intervals) which can be interpreted as the
increase in odds of being selected for progression given a
one point increase in each individual score.
Briefing notes were analysed independently by two
reviewers and arbitrated by a third, to classify each medical
device presented at committee by the device type using five
distinct medical device categorisation systems. The Global
Medical Device Nomenclature (GMDN) [14] and European
Council (EC) Directive [15] classify by the primary mode of
action of the technology; the British National Formulary
(BNF) [16] classifies by body system, and the Food and Drug
Administration (FDA) medical specialty panel [17] and
intended use (dichotomised as diagnostic/therapeutic) clas-
sifies by medical speciality. Associations between each
device classification (using the five described systems) and
the committee decision (i.e. progression to guidance or no
progression), were assessed by Fisher's Exact test, general-
ised for r 2 contingency tables [18]. A significance level of
5% was used for all statistical analysis (i.e. null hypothesis
rejected when Po0.05).
Committee non-progression letters were reviewed inde-
pendently by two reviewers and arbitrated by a third, to
identify the common reasons and their frequency of occur-
rence. Reasons provided by committee for non-progression
were then matched to one or more programme selection
criteria defined in the MTEP Methods Guide [4]. Analysis of
association between the device categories and each indivi-
dual reason for non-progression was also conducted via
Fisher's Exact tests. To take into account the number of
univariate test comparisons being applied (i.e. separate
analysis for each reason given for non-progression), Bonfer-
roni correction was applied to the significance level [19].Results
During the period of January 2010–March 2013, there were
31 committee meetings of which 29 included consideration
of a total of 110 different medical technologies. No medical
devices were re-notified after non-progression during this
period. The majority of sponsors (107/110, 97.3%) were
either the manufacturer or supplier of the medical technol-
ogy; three (2.7%) were sponsored by NHS professionals.
The median number of medical devices considered at
individual committee meetings was 4 [range 1–6]. A non-
significant negative correlation (i.e. reduction) in the
number of medical devices considered at committee over
the 1155 days between the first committee meeting on the
21st January 2010 and the 31st meeting on 21st March 2013
was observed using Pearson's correlation test, r=0.22
[95% CI 0.54 to 0.16].
Of the 110 medical devices reviewed by committee, 45
progressed to full guidance (23 (20.9%) were selected forMTG and 22 (20.0%) were routed for consideration for other
NICE programmes which included 19 to the diagnostics
programme, one to the interventional procedure pro-
gramme, one to clinical guidelines and one to technology
appraisal [20]) and 64 (58.2%) did not progress to guidance
development. A final decision was not given for one product
(0.9%) at the time of analysis and therefore was excluded
from analysis. Figure 1 shows the cumulative ‘progression to
MTG’, ‘progression to guidance in other NICE programmes’,
‘not for progression to guidance’ committee decisions made
during the three year period of interest.
During meetings held between January 2010 and March
2013, no significant correlation was found between the
proportion progressing to guidance and time using Pearson's
correlation test, r=0.07 [95% CI 0.30 to 0.43].
The scoring of medical devices by the NICE technical
team during the preparation of the briefing note was not
introduced until April 2011, therefore only 56 (50%) of the
110 medical devices presented at committee during the
period of interest had briefing note scores completed;
scores for 10 medical devices progressing to MTG develop-
ment, 16 progressing to guidance development in other
programmes and 30 not progressing to guidance were
available for analysis. The median [range] total score for
medical devices selected for progression to guidance devel-
opment was 19 [16,24] and 18 [13,22] for those not
progressing, P=0.53 (Table 1).
For three of the six selection criteria scores, there was
weak evidence to reject the null hypothesis of no difference
(between devices selected for progression versus those
not), but there was no evidence of any differences from
multivariate analysis (i.e. the 95% CI of all odds ratios
included 1.0), Table 1.
There was a significant association between BNF category
and committee progression decision (P=0.02), Table 2,
Table 3 Reasons for a non-progression decision.
Reason for non-progression decision Frequency n (%)
Lack of evidence 60 (93.8)
Insufficient or uncertain benefit to NHS 37 (57.8)
K. Keltie et al.246most likely due to the committee progressing 15/24 (62.5%)
of cardiovascular devices, compared with the overall pro-
gression rate of 41%. There were no significant associations
between GMDN category, primary intended use, EC classifi-
cation or FDA medical specialty panel and committee
progression decision, Supplementary online material 1.Table 1 Results of univariate and multivariate analysis
between medical devices progressing and those not
progressing to NICE guidance development. Odds ratios
are the increase in odds of being selected for progression
for a one point increase in score.
Score compared Univariate Multivariate
Mann–Whitney
P-value
Odds ratio (95%
CI)
Total 0.53 –
Patient benefit 0.05 1.81 (0.72:5.00)
Healthcare system
benefit
0.05 1.74 (0.64:5.09)
Patient population 0.52 0.88 (0.51:1.51)
Disease impact 0.04 1.91 (0.82:4.89)
Cost 0.28 0.85 (0.47:1.51)
Sustainability 0.45 1.34 (0.67:2.76)
Table 2 Classification of medical devices progressing and not progressing to NICE guidance development by British National
Formulary (BNF) device category.
BNF section category Progression (to MTG) Progression (to other NICE
programmes)
Not for progression Total
Cardiovascular 11 4 9 24
Malignant disease and
immunosuppression
1 7 12 20
Wound management product 3 0 6 9
Musculoskeletal and joint disease 2 1 6 9
Obstetrics, gynaecology and urinary-
tract disorders
0 0 5 5
Skin 2 0 3 5
Central nervous system 0 0 4 4
Ear, nose and oropharynx 0 0 4 4
Eye 0 0 3 3
Respiratory 1 3 2 6
Endocrine 0 0 2 2
Infections 0 0 2 2
Nutrition and blood 0 1 2 3
Pregnancy 1 0 1 2
Renal impairment 1 0 1 2
Anaesthesia 0 1 1 2
Immunological products and vaccines 1 0 0 1
Interactions 0 0 1 1
Gastro-intestinal 0 4 0 4
Liver disease 0 1 0 1
Breast-feeding 0 0 0 0
Intravenous additives 0 0 0 0
Borderline substances 0 0 0 0
Total 23 22 64 109
Insufficient or uncertain benefit to
patient
28 (43.8)
Uncertain or no cost benefit 16 (25.0)
Not novel 16 (25.0)
Not clear how technology would be
used in NHS
9 (14.1)
Wrong comparator 9 (14.1)
Lack of plausible promise 9 (14.1)
Usability or technology design issue 8 (12.5)
Design appropriate only to a small
population
6 (9.4)
Inappropriate clinical assumptions 4 (6.2)
Insufficient demand 3 (4.7)
Evidence does not translate to UK
setting
3 (4.7)
Incorrect costing assumptions 3 (4.7)
Potential equality impact issue 3 (4.7)
Total 214
Table 4 Classification by U.S. Food & Drug Administration (FDA) device category grouped by reasons for non-progression (*Po0.003).
Reasons for non-progression [R3.7]
Category Lack of
evidence
Insufficient
or uncer-
tain benefit
to
NHS
Insufficient or
uncertain ben-
efit to patient
Uncertain
or no cost
benefit
Not
novel
Not clear how
technology
would be used in
NHS
Wrong
comparator
Lack of
plausible
promise
Usability or
technology
design issue
Design appro-
priate only to
a small
population
Inappropriate
clinical
assumptions
Insufficient
demand
Evidence does
not translate
to UK setting
Incorrect
costing
assumptions
Potential
equality
impact
issue
FDA panel
category
Anaesthesiology 5 2 1 3 2 0 1 0 1 0 1 0 1 0 1
Cardiovascular 7 4 2 2 3 1 1 1 1 0 0 0 0 1 0
Clinical chemistry
and clinical
toxicology
2 1 2 1 0 1 0 1 0 0 0 1 0 0 0
Ear, nose and
throat
3 2 1 0 2 0 1 0 0 0 0 0 0 0 0
Gastroenterology-
urology
2 0 2 1 1 0 0 2 0 0 1 0 1 0 0
General and
plastic surgery
7 7 8 0 1 1 3 1 0 0 1 0 0 1 0
General hospital
and personal use
5 4 4 2 1 0 0 1 2 0 1 0 0 0 1
Haematology and
pathology
6 5 1 0 1 1 0 0 0 1 0 0 1 0 0
Immunology and
microbiology
2 2 2 1 0 0 0 0 1 0 0 0 0 0 0
Neurological 3 1 1 0 2 2 0 0 1 0 0 0 0 1 0
Obstetrical and
gynaecological
4 3 2 1 0 1 1 1 1 1 0 0 0 0 0
Ophthalmic 3 0 1 0 2 0 0 0 0 1 0 2 0 0 0
Orthopaedic 1 0 0 0 0 0 1 0 0 1 0 0 0 0 0
Physical medicine 6 2 0 2 0 2 1 2 1 1 0 0 0 0 1
Radiology 4 4 1 3 1 0 0 0 0 1 0 0 0 0 0
Total 60 37 28 16 16 9 9 9 8 6 4 3 3 3 3
Fisher's P-value 0.64 0.05 0.00* 0.10 0.26 0.56 0.43 0.46 0.45 0.21 0.71 0.01 0.57 0.83 0.75
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K. Keltie et al.248Fifteen distinct reasons for non-progression were identi-
fied from the commercial in confidence letters provided by
NICE to sponsors of topics not progressing to guidance
development, Table 3. The majority of letters (62/64,
96.9%) contained more than 1 reason for non-progression,
ranging from 1 to 6, with the median number of reasons
being 3.
Grouping the reasons for non-progression into the Pro-
gramme's published selection criteria (Supplementary
online material 2) required further sub-grouping; the
majority (52/60, 86.7%) related to the sponsor notification
inadequately demonstrating the medical device's clinical
effectiveness, and 31/60 (51.7%) and 29/60 (48.3%) related
to insufficient cost evidence and insufficient technical
evidence respectively. A significant association was found
between FDA categories and ‘insufficient or uncertain
benefit to patient reason’ (n=28, P=0.00) reason for non-
progression, Table 4 (i.e. medical devices in some FDA
categories were more likely to obtain this specific reason
for non-progression than other FDA categories). No other
significant associations between medical device cate-
gories and reasons for non-progression were found, see
Supplementary material online 3.Discussion
Of the 110 medical technologies considered by the Medical
Technologies Advisory Committee during its first three
years, approximately one fifth (n=23, 20.9%) were given a
progression decision to Medical Technologies Guidance, and
a similar proportion (n=22, 20.0%) were given a progression
decision to other NICE programmes. The rates of submissionFigure 2 Boxplots showing distribution in individual scores
between medical devices given progression to guidance devel-
opment (red) and not for progression to guidance (blue)
decisions. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of
this article.)to MTEP and proportion selected for progression to guidance
have not changed over time.
The MTEP team introduced a scoring system to inform
committee deliberations. However, we found that the total
score or the scores for any of the six programme categories
(Figure 2) were not associated with decision to progress to
guidance. A limitation of this result is that scores were
available for only half the technologies considered by
committee. Noting this limitation, we speculate that brief-
ing note scores are actually an indication of an innovative
device's ‘potential impact’ in the NHS, allocated before the
evidence is appraised, and that scores correlate poorly with
progression decisions because lack of evidence is the most
common reason cited for non-progression by the commit-
tee. The addition of a criterion to reflect the level and
quality of available evidence may help improve the value of
the scoring exercise and lead to reduced decision times by
the committee.
Application of five internationally recognised medical
device categorisation systems to all 110 medical devices
required independent analysis by two reviewers, arbitration
by a third, and where necessary, the application of addi-
tional rules to ensure that each device was described by a
single category within each system. The difficulty experi-
enced in applying medical device categorisation in this
study highlights that no single medical device categorisation
system is capable of capturing the purpose, primary mode of
action and anatomical location of use of a medical device.
We found a significant relationship between progression
decision and one of the categories (BNF)-due to a slight
tendency to progress cardiovascular devices more often
than others- but found no similar associations with any of
the other categorisations studied, including FDA panel
categories which also includes a cardiovascular category.
Therefore there is little evidence to suggest that the
committee favours or disfavours any particular type of
device when deciding if it should progress to guidance.
The committee provided 15 distinct reasons for non-
progression to the 64 medical devices not selected for
progression to guidance development, the median number of
reasons provided in each non-progression letter was three with
‘lack of evidence’ being provided in almost all (93.8%) cases.
Thematic analysis of the non-progression letters provided by
NICE to the sponsors of medical devices had two main
limitations: firstly, we had to assume that the reasons for no
progression were captured accurately in the letters and
secondly that there is some scope for interpreting programme
selection criteria as overlapping (e.g. claimed healthcare
system benefit and cost considerations). Although it should
be considered in the light of these limitations, we found no
significant associations between reasons given for non-
progression and the six programme selection criteria. In
addition, very few not-for-progression reasons were related
to patient population and none were directly related to
sustainability. Using focus groups, Sprange and Clift [21] found
that manufacturers perceived the publication of negative
guidance from NICE as a risk. Although decision of non-
progression to NICE guidance is not the same as negative
guidance, publication of information about devices not pro-
gressing to guidance may also be perceived as a risk by
companies and therefore discourage new and repeat submis-
sions. In fact, ‘lack of evidence’, rather than an absence of
249Reviewing NICE MTEP progression decisionsplausible promise, was the main reason for non-progression,
but in the early years of the programme, NICE had to trade off
the benefits of full disclosure against the risk of discouraging
new and repeat submissions from companies which would be
contrary to the aims of the programme – to encourage
adoption of novel technologies. Our study, using material
provided directly by NICE, as well as material in the public
domain, has helped to address the question of potential lack of
disclosure of NICE's processes.
No significant correlations were found between individual
reasons for non-progression and time, or device categorisa-
tions (using GMDN, BNF, Intended use, EC Directive and FDA
categorisation methods) and time. One significant associa-
tion was found between FDA category and the “insufficient
or uncertain benefit to patient” reason for non-progression,
even after multiple testing had been accounted for, sug-
gesting weak evidence that there are some categories of
device for which this is reason is given more often than
expected by chance.
We have conducted an extensive analysis of the process
by which MTAC decide to progress or not progress medical
technologies for guidance development during the period
2010–2013. We found no evidence of bias towards particular
types of device in the committee's deliberation process. A
lack of evidence was by far the most common reason given
for non-progression, including for some technologies con-
sidered to be of potential benefit to the NHS. This suggests
that further investment may be justified in infrastructure
which permits companies to work with the NHS to further
develop their evidence base.
As the development and market growth of medical
devices accelerates, so too must the evaluation process
applied by MTEP. This study found that a median of four
medical devices were evaluated by MTAC each month, and
that only one in five received recommendation for MTG
development, and another one in five received recommen-
dation for guidance development in other NICE programmes
(e.g. Diagnostic Guidance). This suggests that further work
is needed to encourage manufacturer submission of medical
devices to the correct NICE programme and to quicken the
evaluation process.Author statements
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